Clough Capital Partners’s Alexion Pharmaceuticals ALXN Stock Holding History

Clough Capital Partners’s Portfolio ALXN Stock Details ALXN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2017 Q4	–	Sell	-77,359	Closed	-$10.9M	–	155
2017 Q3	$10.9M	Sell	77,359 -64,500	-45%	-$8.76M	0.73%	44
2017 Q2	$17.3M	Buy	141,859 +17,159	+14%	+$2M	1.2%	27
2017 Q1	$15.1M	Buy	124,700 +119,800	+2,445%	+$15.4M	0.96%	33
2016 Q4	$600K	Buy	+4,900	New	+$600K	0.04%	139
2016 Q2	–	Sell	-32,350	Closed	-$4.5M	–	251
2016 Q1	$4.5M	Buy	+32,350	New	+$4.75M	0.21%	111
2015 Q3	–	Sell	-58,580	Closed	-$10.6M	–	232
2015 Q2	$10.6M	Buy	+58,580	New	+$10.1M	0.4%	83

Other funds holding ALXN

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return

Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return

Sands Capital Management Arlington, Virginia $25.5B AUM 26.46% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Clough Capital Partners's ALXN Position: Q4 2017 in Review

Clough Capital Partners sold out of Alexion Pharmaceuticals (ALXN) in Q4 2017, closing a stake of 77,359 shares — an estimated $10.9M sold.

Clough Capital Partners first reported a position in ALXN in Q2 2015 and held it in 6 quarters. The position peaked at $17.3M in Q2 2017. 587 funds tracked by Wall St. Rank hold ALXN as of Q4 2017.

Clough Capital Partners reported no remaining Alexion Pharmaceuticals position as of Q4 2017 after selling out during the quarter.
Clough Capital Partners sold 77,359 Alexion Pharmaceuticals shares in Q4 2017, an estimated $10.9M.
Clough Capital Partners first reported a position in Alexion Pharmaceuticals in Q2 2015 and held it in 6 quarters.
Clough Capital Partners's Alexion Pharmaceuticals position peaked at $17.3M in Q2 2017.
587 funds tracked by Wall St. Rank held Alexion Pharmaceuticals as of Q4 2017.

Based on Clough Capital Partners's 13F filing for Q4 2017, filed 14 Feb 2018.